NEW YORK, July 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that it has been added to the Russell Microcap® Index, effective as of the close of the U.S. markets Friday, June 28, 2019.
The Russell Microcap® Index is comprised of the 1,000 smallest market capitalization companies in the Russell 2000® Index plus approximately 500 additional companies.
Additional information on the Russell Microcap® Index and Reconstitution can be found on: https://www.ftserussell.com/resources/russell-reconstitution
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York. For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.
Head of Corporate Communications
Seelos Therapeutics, Inc. (NASDAQ: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022